Navigation Links
Genta Incorporated to Present at the BIO CEO & Investor Conference
Date:2/5/2008

BERKELEY HEIGHTS, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Genta Incorporated (Nasdaq: GNTA) announced today that the Company's Chairman and Chief Executive Officer, Dr. Raymond P. Warrell, Jr., will provide a company overview and update of corporate activities at the BIO CEO & Investor Conference. The presentation is scheduled for Wednesday, February 13th at 3:30 pm ET at the Waldorf Astoria Hotel, New York, NY.

About Genta

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company's research platform: DNA/RNA-based Medicines and Small Molecules. Genasense(R) (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta's Small Molecule program is Ganite(R) (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. Ganite(R) and Genasense(R) are available on a "named-patient" basis in countries outside the United States. For more information about Genta, please visit our website at: http://www.genta.com.

Safe Harbor

This press release may contain forward-looking statements with respect to business conducted by Genta Incorporated. By their nature, forward-looking statements and forecasts involve risks and uncertainties because they relate to events and depend on circumstances that will occur in the future. Forward- looking statements include, without limitation, statements about:

-- the Company's ability to obtain necessary regulatory approval for

Genasense(R) from the U.S. Food and Drug Administration ("FDA") or

European Medicines Agency ("EMEA");

-- the safety and efficacy of the Company's products or product

candidates;

-- the Company's assessment of its clinical trials;

-- the commencement and completion of clinical trials;

-- the Company's ability to develop, manufacture, license and sell its

products or product candidates;

-- the Company's ability to enter into and successfully execute license

and collaborative agreements, if any;

-- the adequacy of the Company's capital resources and cash flow

projections, and the Company's ability to obtain sufficient financing

to maintain the Company's planned operations;

-- the adequacy of the Company's patents and proprietary rights;

-- the impact of litigation that has been brought against the Company and

its officers and directors and any proposed settlement of such

litigation;

-- the Company's ability to regain compliance with the NASDAQ's listing

qualifications; and

-- the other risks described under Certain Risks and Uncertainties Related

to the Company's Business, as contained in the Company's Annual Report

on Form 10-K and Quarterly Report on Form 10-Q.

The Company does not undertake to update any forward-looking statements. There are a number of factors that could cause actual results and developments to differ materially. For a discussion of those risks and uncertainties, please see the Company's Annual Report on Form 10-K for 2006 and its most recent quarterly report on Form 10-Q.

CONTACT:

Nichol Harber

Genta Investor Relations

908-286-3980

info@genta.com


'/>"/>
SOURCE Genta Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
2. Syngenta Licenses Chromatin Gene Stacking Technology
3. Genta Completes Appeal of FDA Decision for Genasense(R) in CLL
4. Genta Receives Notice of Non-Compliance with Listing Requirement for NASDAQ Global Market
5. Syngenta and The Royal Society of Chemistry Launch African Science Initiative
6. Genta Incorporated to Present at Lazard Capital Markets 4th Annual Healthcare Conference
7. Genta Receives NASDAQ Non-Compliance Notice
8. Genta Receives Notice of Non-Compliance With NASDAQ Rule
9. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
10. MultiCell Technologies Signs Worldwide Exclusive License Agreement With Corning Incorporated
11. Accuray Incorporateds CEO to Speak at Piper Jaffray 19th Annual Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... , March 1, 2017  Friends, family, healthcare ... with multiple sclerosis (MS), a chronic condition affecting the ... MSWorld , MS Views and News , ... Multiple Sclerosis Foundation — have joined biotechnology company ... through the #MySupportHero initiative. During MS Awareness Month, there ...
(Date:3/1/2017)... Young and Joshua Rosenthal , PhD, of RowdMap, ... Workforce Speaker series. http://bit.ly/2lA6C8B Elizabeth Young ... on March 9, 2017 at the Milken Institute School ... at 12:00pm. The George Washington University,s ... examine new workforce configurations, their outcomes and associated challenges. ...
(Date:2/28/2017)... VILLAGE, Calif. , Feb. 28, 2017   ... dermatology and aesthetics company, is pleased to announce that ... special advisor to Sienna,s CEO and Board of Directors. ... chairman and chief executive officer of Allergan for 17 ... his return to dermatology and aesthetics. "I ...
(Date:2/28/2017)... 2017  Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical ... of autoimmune diseases, asthma and allergic diseases and ... quarter and full year ended December 31, 2016 ... business and clinical highlights. "During 2016, ... pipeline by starting five clinical trials across our ...
Breaking Biology Technology:
(Date:2/7/2017)... , Feb. 7, 2017   MedNet Solutions ... the entire spectrum of clinical research, is pleased to ... , its innovative, highly flexible and award winning ... customers. iMedNet is a proven Software-as-a-Service ... Electronic Data Capture (EDC), but also delivers an entire ...
(Date:2/3/2017)... -- Texas Biomedical Research Institute announced that its Board of Trustees ... the Institute,s new President and CEO. Dr. Schlesinger will take ... is currently the Chair of the Department of Microbial Infection ... Biology at Ohio State University. "We are delighted ... of Texas Biomed," said Dr. James O. Rubin , ...
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
Breaking Biology News(10 mins):